Patents Examined by Evelyn Rabin
  • Patent number: 6015695
    Abstract: There is provided an isolated immunoglobulin comprising two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, wherein the immunoglobulin is further devoid of light polypeptide chains.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 18, 2000
    Assignee: Vrije Universiteit Brussel
    Inventors: Cecile Casterman, Raymond Hamers
  • Patent number: 6015554
    Abstract: The invention relates to methods of enriching for hematopoietic cell populations enriched in myeloid and/or lymphoid progenitor cells based on cell specific markers. The methods also provide an enriched population of prethymic lymphoid-committed progenitor population lacking long-term hematopoietic reconstitution potential. Compositions enriched for the cells and populations of cells obtained therefrom are also provided by the invention. Methods of use of the cells are also included. Methods of genetically modifying the cells are provided as are cells obtained thereby.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 18, 2000
    Assignee: SyStemix, Inc.
    Inventor: Anne H. M. Galy
  • Patent number: 6005079
    Abstract: There is provided an isolated immunoglobulin comprising two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, wherein the immunoglobulin is further devoid of light polypeptide chains.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 21, 1999
    Assignee: Vrije Universiteit Brussels
    Inventors: Cecile Casterman, Raymond Hamers
  • Patent number: 5985660
    Abstract: The invention relates to methods of enriching for hematopoietic cell populations enriched in myeloid and/or lymphoid progenitor cells based on cell specific markers. The methods also provide an enriched population of prethymic lymphoid-committed progenitor population lacking long-term hematopoietic reconstitution potential. Compositions enriched for the cells and populations of cells obtained therefrom are also provided by the invention. Methods of use of the cells are also included. Methods of genetically modifying the cells are provided as are cells obtained thereby.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 16, 1999
    Assignee: SyStemix, Inc.
    Inventor: Anne H. M. Galy
  • Patent number: 5976810
    Abstract: A reagent for immunologically detecting rheumatism containing as an antigen at least one mammalian protein selected from among ezrin, radixin and moesin and/or a peptide composed of at least nine consecutive amino acid residues found in the amino acid sequences of ezrin, radixin and moesin; and a method of detecting autoantibodies present in the serum of a rheumatic. An immunological reaction using this reagent enables precritical or early diagnosis of rheumatism. An immunological detection using the above autoantigenic proteins is convenient and reliable as an early serodiagnostic method based on rheumatism-specific antigens.
    Type: Grant
    Filed: May 8, 1997
    Date of Patent: November 2, 1999
    Assignee: Hoechst Pharmaceuticals & Chemicals K.K.
    Inventors: Masako Wagatsuma, Michio Kimrua, Hiroshi Watanabe, Fujio Takeuchi
  • Patent number: 5972627
    Abstract: The invention relates to methods of enriching for hematopoietic cell populations enriched in myeloid and/or lymphoid progenitor cells based on cell specific markers. The methods also provide an enriched population of prethymic lymphoid-committed progenitor population lacking long-term hematopoietic reconstitution potential. Compositions enriched for the cells and populations of cells obtained therefrom are also provided by the invention. Methods of use of the cells are also included. Methods of genetically modifying the cells are provided as are cells obtained thereby.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 26, 1999
    Assignee: SyStemix, Inc.
    Inventor: Anne H. M. Galy
  • Patent number: 5958410
    Abstract: Sarcoidosis is associated with CD4.sup.+ T lymphocytes which express the T cell receptor V.sub..alpha. 2.3 chain. Thus, a method for diagnosing sarcoidosis is provided which comprises contacting cells of a subject with a first monoclonal antibody, or an antigen-binding fragment or derivative, specific for an epitope of the variable region of the T cell receptor V.sub..alpha. 2.3 chain and detecting the binding of the antibody. Also provided is a method for treating sarcoidosis in which a monoclonal antibody, or an antigen-binding fragment or derivative thereof, specific for an epitope of the variable region of the T cell receptor V.sub..alpha. 2.3 chain is administered. Sarcoidosis is also treated by administering a therapeutically effective amount of a protein or a peptide comprising an amino acid sequence of the variable region of the T cell receptor V.sub..alpha. 2.3 chain, or a functional derivative of the protein or peptide, or an antisense oligonucleotide which is complementary to the T cell receptor V.
    Type: Grant
    Filed: November 6, 1995
    Date of Patent: September 28, 1999
    Assignee: Avant Immunotherapeutics, Inc.
    Inventors: Hans Wigzell, Johan Grunewald, Carl Harald Janson, Nancy Jones
  • Patent number: 5928643
    Abstract: Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 27, 1999
    Assignee: Biogen, Inc.
    Inventors: Barbara P. Wallner, Glenn T. Miller, Margaret D. Rosa
  • Patent number: 5928893
    Abstract: A monoclonal antibody specific for human 4-1BB, accessory molecule, selectively expressed on activated T cells; polynucleotides encoding the variable regions of the monoclonal antibody and amino acid sequences deduced therefrom; a hybridoma cell line producing the monoclonal antibody; and a process for preparing the hybridoma cell line.
    Type: Grant
    Filed: November 13, 1996
    Date of Patent: July 27, 1999
    Assignee: LG Chemical Ltd.
    Inventors: Chang-Yuil Kang, Joong-Gon Kim
  • Patent number: 5919665
    Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: July 6, 1999
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventor: James A. Williams
  • Patent number: 5919637
    Abstract: A method using compounds inhibiting binding reactions involving GMP-140 to modulate an inflammatory response. The method is based on the discovery that GMP-140, released from the storage granules of platelets, endothelial cells, and megakaryocytes, and redistributed to the surface of the cells within seconds of activation by mediators such as thrombin, ionophores or histamine, binds to a ligand on neutrophils, and the plasma proteins C3b and protein S. Adhesion of the cells following activation is blocked directly by administration of antibody to GMP-140 or its ligand, or by competitive inhibition by administration of soluble GMP-140, the GMP-140 ligand, or the specific carbohydrate portion of the ligand bound by GMP-140.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: July 6, 1999
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Rodger P. McEver
  • Patent number: 5914261
    Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: June 22, 1999
    Assignees: Regeneron Pharmaceuticals, Inc., Board of Regents, University of Texas System
    Inventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
  • Patent number: 5914111
    Abstract: Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: June 22, 1999
    Assignee: Biogen Inc.
    Inventors: Barbara P. Wallner, Glenn T. Miller, Margaret D. Rosa
  • Patent number: 5912133
    Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1a (murine flk-2), FIG. 1b (human flk-2) and FIG. 2 (murine flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1a, FIG. 1b and FIG. 2; ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation and/or differentiation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.
    Type: Grant
    Filed: February 10, 1998
    Date of Patent: June 15, 1999
    Assignee: The Trustees of Princeton University
    Inventor: Ihor R. Lemischka
  • Patent number: 5910309
    Abstract: The present invention comprises the method of selectively suppressing an immune response of a mammal to a particular alloantigen. The method includes several steps. One step is administering to a mammal an effective amount of UVB-radiation. It is demonstrated herein UVB radiation selectively suppresses the DTH response in mammals. Epidermal cell cultures, when subjected to UVB irradiation (280 nm to 320 nm) produce a specific immunosuppressive factor. The immunosuppressive factor is reactive with an antibody directed toward IL-10. Another step of the inventive method involves desensitizing a mammal to a particular alloantigen. It has been determined that a mammal will become tolerant to a particular alloantigen once the subject mammal has been irradiated with a pre-determined wavelength of UVR and thereafter sensitized with the particular alloantigen. This may analogously be accomplished using the immunosuppressive factor from in vitro epidermal cell cultures of the present invention.
    Type: Grant
    Filed: May 1, 1995
    Date of Patent: June 8, 1999
    Assignee: Board Of Regents, The University Of Texas System
    Inventor: Stephen E. Ullrich
  • Patent number: 5891439
    Abstract: Novel polypeptides having lymphocyte stimulating factor activity are disclosed, as well as the use thereof for treating African sleeping sickness. Also, the corresponding nucleic acid sequences are provided as well as truncated forms which encode polypeptides exhibiting enhanced biological activity.
    Type: Grant
    Filed: July 26, 1996
    Date of Patent: April 6, 1999
    Assignees: SBL Vaccin AB, Stockholm, SE, University of Iowa Research Foundation Inc.
    Inventors: Tushar Vaidya, Abdel-Moiz Bakhiet, Tomas Olsson, Krister Kristensson, John E. Donelson
  • Patent number: 5885575
    Abstract: The inventon relates to antibodies that react with a variant epilope in the extracellular region of a variant CD44 polypeptide, wherein the variant epitope has the amino acid sequence:I S S T I S T T P R A P D H T K Q N Q D W T Q W N P S H S N P EV L L Q T T T R M T D V D R N G T T A Y E G N W N P E A H P P LI H H E H H E E E E T P H S T S T I O A T P S S T T E E T A T QK E Q W F G N R W H E G Y R Q T P R E D S H S T T G T A A A S AH T S H P M Q G R T T P S P E D S S W T D F F N P I S H P M G RG H Q A G R R (residues 53-219 of SEQ ID NO:4). Methods of using the antibodies to identify variant epitopes also are provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 23, 1999
    Assignees: Kernforschungszentrum Karlsruhe GmbH, Universitaet Karlsruhe, Deutsches Krebsforschungszentrum
    Inventors: Peter Herrlich, Helmut Ponta, Ursula Guenthert, Siegfried Matzku, Achim Wenzel
  • Patent number: 5885574
    Abstract: Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.
    Type: Grant
    Filed: July 26, 1994
    Date of Patent: March 23, 1999
    Assignee: Amgen Inc.
    Inventor: Steven G. Elliott
  • Patent number: 5879899
    Abstract: The present invention provides methods of assaying the human DNA repair enzyme O.sup.6 -methylguanine-DNA methyltransferase (MGMT) and/or active site alkylated derivatives thereof (R-MGMT), which rely on the ability of a protease, e.g., V8 Protease (also referred to as Glu-C Protease), to distinguish between these two enzyme forms. Such a method comprises the steps of: (a) contacting the sample with a protease to which one of human MGMT and R-MGMT is preferentially sensitive; and (b) determining whether the treated sample contains one or more polypeptides selected from (I) at least one polypeptide fragment characteristic of action of the protease on the protease-sensitive form of human MGMT and (ii) the protease-resistant form of human MGMT.
    Type: Grant
    Filed: September 16, 1996
    Date of Patent: March 9, 1999
    Assignee: National University of Singapore
    Inventor: Benjamin F. Li
  • Patent number: 5876949
    Abstract: The present invention relates to substantially pure FXR1 and FXR2 proteins and isolated nucleic acid molecules encoding the same. Recombinant expression vectors comprising nucleic acid sequences that encode FXR1 and FXR2 protein are also provided. Antibodies which bind to an epitope of FXR1 or FXR2, or FMR1 protein are also provided. The present invention also relates to methods of screening individuals for FMR1 deficiency using antibodies or nucleic acid molecules of the invention and pharmaceutical kits for accomplishing the same.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: March 2, 1999
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Mikiko C. Siomi, Yan Zhang